Loading...
•
Dec 31, 2020
Praxis Q4 2020 Earnings Report
Praxis Precision Medicines reported financial results for the fourth quarter and full year 2020 and provided a corporate update.
Key Takeaways
Praxis Precision Medicines reported a net loss of $25.7 million for the fourth quarter of 2020. As of December 31, 2020, the company had $296.6 million in cash and cash equivalents. The company's cash and cash equivalents as of December 31, 2020 are expected to fund operations into the fourth quarter of 2022.
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance.
PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021.
Innovative collaboration with The Florey Institute expands pipeline via addition of 3 ASOs targeting rare epilepsies.
Cash Balance of $296.6M as of December 31, 2020 supports cash runway into 4Q22.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...